<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364002">
  <stage>Registered</stage>
  <submitdate>6/04/2013</submitdate>
  <approvaldate>15/04/2013</approvaldate>
  <actrnumber>ACTRN12613000411741</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of chloroquine for the treatment of Plasmodium vivax malaria in Teyarett District in Nouakchott and in the city of d'Atar (Adra Province) in Mauritania. </studytitle>
    <scientifictitle>Efficacy and safety of chloroquine for the treatment of Plasmodium vivax malaria in Teyarett District in Nouakchott and in the city of d'Atar (Adra Province) in Mauritania. </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Plasmodium vivax malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Efficacy and safety of  a total oral dose of 25 mg base per kg body weight of chloroquine over three consecutive days: 10 mg base on day  1 and day 2, and 5 mg base per kg on day 3.  Each daily dose administration will be administered orally under supervision, and patients will be followed up for 28 days for  clinical and parasitological assessments.  </interventions>
    <comparator>none</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cure rate in terms of adequate clinical and parasitological response at day 28 as determined by clinical examination and blood  microscopy</outcome>
      <timepoint>day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>incidence of adverse events as reported by patients or observed by investigators. Clinical laboratory studies may be reqired to confirm a diagnosis or to follow-up an adverse event.</outcome>
      <timepoint>day 28</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>age 6 months and older
mono-infection with P vivax detected by microscopy
asexual parasite count greater than 250 per microliter
axillary temperature greater than 37.5 degrees Celsius or history of fever during the 48 hours before recruitment
able to swallow oral medication
able and willing to comply with the protocol and schedule of assessments
informed consent 


</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>clinical condition due to vivax malaria (coma, respiratory distress syndrome or severe anaemia) requiring hospitalisation
severe malnutrition according to WHO child growth standards
febrile condition due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe disease
history of hypersensitivity reactions to any medicine tested 
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/10/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Mauritania</country>
      <state>Teyarett/Nouakchott</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mauritania</country>
      <state>Atar/ Adrar province (2)</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Ministry of Health of Mauritania</primarysponsorname>
    <primarysponsoraddress>P.O. Box  169
Nouakchott
Mauritania</primarysponsoraddress>
    <primarysponsorcountry>Mauritania</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Ministry of Health of Mauritania</fundingname>
      <fundingaddress>P.O. Box  169
Nouakchott
Mauritania</fundingaddress>
      <fundingcountry>Mauritania</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>World Health Organisation</fundingname>
      <fundingaddress>20 avenue Appia
CH 1211 Geneva 27
Switzerland</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a therapeutic efficacy study of chloroquine, the current first line drug for the treatment of P vivax malaria in Mauritania. The results will be used to formulate recommendations and to enable the Ministry of Health to make informed decisions about whether the current national antimalarial treatment guidelines should be updated</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>World Health Organisation Ethics Review Committee (WHO ERC)</ethicname>
      <ethicaddress>20 Avenue Appia
Ch 1211 Geneva 27
Switzerland</ethicaddress>
      <ethicapprovaldate>28/03/2013</ethicapprovaldate>
      <hrec>RPC 566</hrec>
      <ethicsubmitdate />
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Mamadou Dit Dialaw</name>
      <address>P.O. Box 169 
Nouakchott
Mauritania</address>
      <phone>+ 222 22 11 70 31</phone>
      <fax />
      <email>mamadouditdialawaba@yahoo.fr</email>
      <country>Mauritania</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mamadou Dit Dialaw</name>
      <address>P.O. Box 169 
Nouakchott
Mauritania</address>
      <phone>+ 222 22 11 70 31</phone>
      <fax />
      <email>mamadouditdialawaba@yahoo.fr</email>
      <country>Mauritania</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mamadou Dit Dialaw</name>
      <address>P.O. Box 169 
Nouakchott
Mauritania</address>
      <phone>+ 222 22 11 70 31</phone>
      <fax />
      <email>mamadouditdialawaba@yahoo.fr</email>
      <country>Mayotte</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Pascal Ringwald</name>
      <address>20 avenue Appia
CH1211 Geneva 27
Switzerland</address>
      <phone>+ 41 22 791 3469</phone>
      <fax />
      <email>ringwaldp@who.int</email>
      <country>Switzerland</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>